119th (2025–2027)
H.R. 9547
This bill directs the Secretary of Defense to report to Congress within 180 days on emerging treatment options for treatment-resistant PTSD in active-duty servicemembers, veterans, and transitioning servicemembers. The report must examine safety data, dosing information, and feasibility of findings from an Arizona-based clinical trial testing psilocybin mushrooms as a PTSD treatment, and assess how this research could apply to military personnel. The bill requires the Defense Department to analyze implications for force health, medical readiness, and suicide prevention, evaluate legal pathways for potential expanded access to investigational treatments, and outline resource needs and timelines for any future pilot programs beginning in fiscal year 2027. The Assistant Secretary of Defense for Health Affairs must coordinate this report with the Veterans Affairs Department, Health and Human Services, the FDA, and the DEA, and submit it in unclassified form to the congressional defense committees.